Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional studyLothar Bergmann, Michael Staehler, Ulrich Kube et al.|BMC Cancer|2015Cited by 23
Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional StudyLothar Bergmann, Christian Doehn, Thomas Steiner et al.|Oncology Research and Treatment|2013Cited by 15
Everolimus as second-line therapy for metastatic renal cell carcinoma (mRCC) after one previous VEGF-targeted therapy: Final results of the noninterventional change study.Peter J. Goebell, Lothar Bergmann, Ulrich Kube et al.|Journal of Clinical Oncology|2014Cited by 5
Updated results of a prospective noninterventional study of everolimus after use of 1 VEGFR-TKI.Lothar Bergmann, Christian Doehn, Peter J. Goebell et al.|Journal of Clinical Oncology|2012Cited by 1
Mitteilungen onkologischer Gesellschaften · Reports of Oncological SocietiesChristoph‐Thomas Germer, Ingo Hartlapp, Hermann Einsele et al.|Onkologie|2013Cited by 0